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AbstrAct
Targeting specifically primary prostate cancer (PCa) cells for immune therapy, 
gene therapy or molecular imaging is of high importance. The PCA3 long non-coding 
RNA is a unique PCa biomarker and oncogene that has been widely studied. This 
gene has been mainly exploited as an accurate diagnostic urine biomarker for PCa 
detection. In this study, the PCA3 promoter was introduced into a new transcriptional 
amplification system named the 3-Step Transcriptional Amplification System (PCA3-
3STA) and cloned into type 5 adenovirus. PCA3-3STA activity was highly specific for 
PCa cells, ranging between 98.7- and 108.0-fold higher than that for benign primary 
prostate epithelial or non-PCa cells, respectively. In human PCa xenografts, PCA3-
3STA displayed robust bioluminescent signals at levels that are sufficient to translate 
to positron emission tomography (PET)-based reporter imaging. Remarkably, when 
freshly isolated benign or cancerous prostate biopsies were infected with PCA3-3STA, 
the optical signal produced from primary PCa biopsies was significantly higher than 
from benign prostate biopsies (4.4-fold, p < 0.0001). PCA3-3STA therefore represents 
a PCa-specific expression system with the potential to target, with high accuracy, 
primary or metastatic PCa epithelial cells for imaging, vaccines, or gene therapy.
INtrODUctION
Inrecent years, wide-array genomic analysis has 
provided a better understanding of the molecular changes 
occurring during prostate epithelial cell transformation 
and progression in aggressive cancers [1]. Exploitation of 
these transcriptional alterations in vivo is among several 
approaches, which can be used to better treat, prognose, or 
image prostate cancers (PCa) [2-4]. The prostate provides 
a unique anatomical location to deliver transcription 
expression-based nanotechnologies directly into the 
organ through transrectal ultrasound-guided injections, 
thereby avoiding systemic biodistribution and poor target 
delivery [5]. However, the relatively weak activity of 
many tumor-specific promoters has limited this approach. 
To circumvent this limitation, investigators have used 
several techniques to amplify promoter signals [3, 6, 7]. 
One of these approaches, the two-step transcriptional 
amplification (TSTA) system, has been successfully 
adapted for optical and PET-based molecular imaging as 
well as for gene therapy [7-10]. We recently demonstrated 
that the amplification provided by the TSTA driven by 
the prostate specific antigen (PSA) promoter (PSEBC) 
was strong enough to image transcriptional activity in the 
prostate of large immunocompetent mammals following 
ultrasound-guided transrectal injection and using a clinical 
PET imaging apparatus [5]. Despite the high translational 
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potential of these technologies, their ability to detect 
primary PCa in vivo remains unchartered territory. 
PCA3/DD3 long non-coding RNA (lncRNA) is an 
oncogene overexpressed by up to 60-fold in PCa compared 
to benign epithelial cells [11, 12]. Its abundant expression 
in PCa is controlled in part through transcription and 
is expressed from precancerous lesions (prostatic 
intraepithelial neoplasia (PIN)) to metastases [13, 14]. In 
the clinical setting, it is used as a promising biomarker 
and as an adjunct to serum PSA or to magnetic resonance 
imaging to determine the risk of PCa prior to biopsy [15, 
16]. Unfortunately, because of its weak activity, the PCA3 
promoter was not successfully exploited to target PCa 
cells.
In this study, we present a new transcriptional 
amplification system, referred to as 3STA (three-step 
transcriptional amplification), which boosts expression 
from PCA3 promoter-directed construct up to a hundred-
fold, achieving better amplification and specificity than 
does the current benchmark TSTA method. When driven 
by the PCA3 promoter, the 3STA allows for sensitive 
primary PCa detection, thus significantly improves the 
translational potential of the PCA3 transcription-based 
PCa-specific diagnosis, imaging, and therapy.
rEsULts 
PCA3-3STA is a highly amplified expression 
system
Because the expression of PCA3 lncRNA is prostate-
restricted and highly amplified specifically in PCa, it is 
Figure 1: The Three-Step-Transcriptional Amplification system provides strong amplification of the PCA3 promoter 
activity. A. Scheme of non-replicative reporter adenoviruses. b. The amplification provided by the 3STA was significantly higher than that 
of the TSTA. PCa cells (22Rv1, LAPC4, PC-3, DU145) were infected with PCA3-fl, PCA3-TSTA, or PCA3-3STA. Cells were harvested 
after 72 h of infection. The relative fl activity (RLU) was normalized by protein content in each well divided by the SV40 promoter activity 
in each cell line (RLU = (RLU/μg protein) ÷ (RLU SV40/μg)*100). Each data represents triplicates ± SD; *p < 0.05, **p < 0.01.
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rational to exploit the specificity of its promoter in PCa 
diagnostic or therapeutic approaches. Unfortunately, PCA3 
promoter activity is weak and as a result has not raised 
much interest [17, 18]. To address this limitation, we first 
investigated whether its activity could be amplified once 
introduced within a transcriptional amplification system 
such as the TSTA (Figure 1A and 1B). 
The TSTA system has three components: a specific 
promoter (e.g. PCA3 promoter), an amplifier (GAL4VP16 
fusion protein), and a reporter gene (Figure 1A). The 
specificity of TSTA is dictated by the promoter that drives 
GAL4VP16 to initiate the transcriptional amplification of 
the system. Because Verhaegh et al. have shown that the 
minimal region (-152 to +62 bp of AF279290 sequence) 
of the PCA3 promoter was more active in the PCa LNCaP 
cell line than other non-PCa cells, we have used this 
sequence as a driver of the TSTA system. As expected, 
when the PCA3 proximal promoter (-152 to +62 bp) was 
cloned into the TSTA, its observed activity was higher 
than the non-amplified promoter (Figure 1B). However, 
the amplification provided was mild in the LAPC4, PC-3, 
and DU145 PCa cell lines.
To further increase the amplification provided by the 
TSTA, five copies of the GAL4-response elements and the 
adenoviral E4 gene minimal promoter [19] were cloned 
upstream of the PCA3 promoter (Figure 1A). This system, 
referred to as the 3-Step Transcriptional Amplification 
system (3STA), amplifies the PCA3 promoter in three 
steps: (1) production of the GAL4VP16 fusion protein 
under the control of the PCA3 promoter; (2) binding of 
GAL4VP16 onto the GAL4 response element (GAL4RE) 
upstream of the GAL4VP16 and firefly luciferase (fl) 
genes; and (3) overexpression of the GAL4VP16 to further 
amplify fl reporter gene expression as a positive feedback 
loop (Figure 1A). Since the TSTA activator and amplifier 
cassette orientations within the viral genome have been 
shown to be important for signal specificity [20], we 
compared the activator and amplifier cassette orientations 
and their respective activities in four cancer cell lines 
(Figure S1A). As shown (Figure S1B), the tail-to-tail (TT) 
orientation provided the best amplification signal without 
changing the PCA3-3STA specificity for the PCa cell lines. 
Hence, we used the PCA3-3STA-TT conformation for all 
of our subsequent studies. As shown in Figure 1B, the fl 
activity of the PCA3-3STA is dramatically amplified. In 
fact, PCA3-3STA was shown to amplify reporter activity 
by 94.5- and 20.2-fold, compared to that of PCA3-Luc, 
and 2.3 and 7.6-fold compared to that of PCA3-TSTA in 
22Rv1 and LAPC4, respectively. 
PCA3-3STA directs a robust expression that is 
specific to prostate cancer
Next, we assessed the PCa specificity of our PCA3-
3STA construct by comparing its expression level in PCa 
cell line 22Rv1 to that in the bladder cancer cell line 
SW780. We first showed that adenoviral infectivity is 
comparable in 22Rv1 (PCa) and SW780 (bladder cancer) 
cells as infection with increasing multiplicity of infection 
(MOI) of a constitutive CMV-driven green fluorescent 
protein (GFP) adenovirus showed comparable GFP 
expression (Figure 2A). In contrast, using a PCA3-3STA 
driven fl adenovirus, the fl activity increased with MOI 
only in the PCa cells (Figure 2B). The highly amplified 
PCA3-3STA activity was restricted to PCa cell lines 
(22Rv1, LAPC4, PC-3 and DU145) but remained inactive 
in benign prostate cell lines (PZ-HPV7 and WPMY-1) 
and non-prostate carcinoma cell lines such as SW780 
(bladder), MGHU3 (bladder) and HepG2 (hepatic) (Figure 
1B and 2C). Remarkably, the 22Rv1/SW780 activity 
ratio (specificity ratio) increased from 2.6 for PCA3-Luc 
alone to 108.0 with PCA3-3STA (Figure 2C, not shown 
for PCA3-Luc). Furthermore, PCA3-3STA exhibited 
negligible activity in primary benign prostate epithelial 
cells harvested from prostate biopsies (NPC1, and NPC2, 
specificity ratio 22Rv1/NPC2=98.7)) which are not 
immortalized by viral proteins as in the case of PZ-HPV7 
and WPMY-1 (Figure 2D). 
Next we assessed the androgen inducibility of 
PCA3-driven amplification system, which in turn would 
inform us on its utility in targeting castration-resistant 
PCa cells (CRPC). As shown in (Figure 2E and 2F) the 
androgen-responsive PSA-derived PSEBC-TSTA activity 
[21] was highly induced in the presence of androgen 
(DHT) over that under AR blockade (with bicalutamide) 
in both LAPC4 and 22Rv1 (13.81- and 2.69-fold, 
respectively). In contrast, PCA3-3STA system is not 
androgen dependent. Upon DHT treatment of LAPC4 
and 22Rv1, its activity was 1.98- and 0.68-fold that of 
without DHT, respectively (Figure 2E and 2F). Moreover, 
contrary to PSEBC-TSTA, PCA3-3STA remained active 
in androgen receptor (AR)-negative prostate cancer 
cells (PC-3 and DU145, Figure 1B and 2C) while it 
was silent in AR-positive breast cancer cells (CAMA-1, 
Supplemental Figure S2). A prerequisite of robust in vivo 
activity is the ability to maintain persistent expression in 
cells. Thus, we characterized the dynamics of the 3STA 
system in a time course experiment conducted for 96h and 
compared it with the TSTA system (Figure S3). PCA3-
TSTA and PCA3-3STA displayed similar amplifications 
during 48h, after which time the PCA3-TSTA reached a 
plateau while PCA3-3STA activity continued to increase. 
This correlated with a higher level of GAL4VP16 protein 
at 72 and 96h for the 3STA, indicating that the enhanced 
amplification was due in part to the higher activation of 
the 3STA system by the increased GAL4VP16 protein 
expression (Figure S3).
To this point, our data demonstrated that the novel 
PCA3-3STA system we have generated can amplify 
expression via PCA3 promoter by over 95-fold. But, 
importantly, this transcriptionally-based gene expression 
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Figure 2: PCA3-3STA: A prostate- and prostate cancer-specific expression system that is not androgen-dependent. A. 
PCA3-3STA specificity for PCa cells was not due to differences in cell line-specific infectivity. 22Rv1 (PCa) and SW780 (Bladder Ca) cells 
were infected with CMV-GFP adenovirus at 1, 5, and 10 MOI, and the percentage of GFP expression was found to be comparable in both 
cell lines. b. PCA3 amplified activity in PCa specificity is not due to enhanced PCa transduction by adenovirus. 22Rv1 and SW780 cells 
were infected with PCA3-3STA at 1, 5, and 10 MOI. c. PCA3-3STA is highly active in all PCa cell lines tested. PCa (22Rv1, LAPC4, PC-3, 
DU145), non-PCa (SW780, HepG2), and non-cancerous prostate (PZ-HPV-7, WPMY-1) cells were infected with PCA3-3STA at 5 MOI. 
Cells were harvested after 72 h of culture. D. PCA3-3STA activity was higher in cancerous than in benign prostate epithelial cells. PCa cells 
and two primary prostate epithelial cell cultures were infected with PCA3-3STA at 5 MOI. E. and F. PCA3-3STA was prostate specific and 
not androgen dependent when compared to PSEBC-TSTA. Androgen receptor positive PCa cells (22Rv1 or LAPC4) were infected with 
either PSEBC-TSTA or PCA3-3STA at 5 MOI and treated with either DHT (10 nM) or bicalutamide (10 μM). The relative fl activity (RLU) 
was normalized by protein content in each well divided by the SV40 promoter activity in each cell line (RLU = (RLU/μg protein) ÷ (RLU 
SV40/μg)*100). Each result represents triplicates ± SD; *p < 0.05, **p < 0.01, **** p = < 0.0001.
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system maintained exquisite PCa-specificity that does not 
rely on androgens for its activity. 
PCA3-3STA directs a robust expression in vivo in 
PCa tumor models
Because one of the most promising applications of 
the PCA3-3STA system is in intraprostatic imaging, we 
compared its activity in vivo with that of the PSEBC-
TSTA system which we showed as being sensitive enough 
to image intraprostatic PSA promoter activity by PET in 
large immunocompetent mammals [5]. Figure 3 shows 
that following intratumoral injections of PCA3-3STA 
in 22Rv1 and LAPC4 mice xenografts, we were able to 
detect a strong bioluminescent signal comparable to that 
of the PSEBC-TSTA system, which suggests that PCA3-
3STA may be sensitive enough to image intraprostatic 
PCA3 transcriptional activity by PET [5]. 
PCA3-3STA can detect primary PCa 
In another key step to ensure the significant clinical 
translational potential of this system, we tested the capacity 
of PCA3-3STA to target primary PCa cells, as most of the 
cell lines tested were isolated from metastatic PCa. For 
this purpose, biopsies were taken from cancer-bearing 
prostates following a radical prostatectomy or from benign 
prostates following a radical cystoprostatectomy (surgery 
performed to remove urinary bladder and prostate gland 
from bladder cancers patients) and the resulting samples 
were cultured for 72h in the presence of the PCA3-3STA 
adenovirus (Figure 4). As shown in Figure 4B and 4C, 
PCa cells kept PSA and AMACR expression and kept 
proliferating (as depicted by positive Ki67 staining) 
despite adenoviral infection. Moreover, the location of 
luciferase expression was confirmed to be located into 
PCa cells by IHC while stromal cells did not express the 
reporter gene (Figure 4B and 4C). More interestingly, 
a statistically significant higher fl signal was observed 
within the primary PCa biopsies than in the benign 
prostate biopsies harvested from radical cystectomy 
specimens (Figure 5). When the luciferase activities of 
PCA3-3STA transduced biopsies harvested from PCa 
patients were compared to that of non-PCa patients, the 
fl activity was 4.4-fold higher in the PCa biopsy-group 
(Figure 5A and 5B, Average radiance 35 649±17 919 p/s/
cm2) than in the non-PCa biopsy group (Average radiance 
8 072±8940 p/s/cm2) and the difference was statistically 
significant (p < 0.0001). Because PCa is not uniformly 
spread through the glands and the density of prostate 
epithelial cells could be responsible for the observed 
difference between benign and malignant tissues, we also 
Figure 3: PCA3-3STA provided reporter expression levels in vivo comparable to those of the PSEBC-TSTA system. 
22Rv1 and LAPC4 PCa cell subcutaneous xenografts were generated in SCID beige mice. Following tumor growth and mice randomization 
for tumor volume, 108 ivp of either PCA3-3STA or PSEBC-TSTA were injected intratumorally. After 96 h, reporter activity was assessed 
by bioluminescence. Average photon emission per tumor was measured in 22Rv1 and LAPC4 mouse xenografts (n = 3). No statistically 
significant difference was observed between the PCA3-3STA and PSEBC-TSTA fl activity in the two cell lines tested.
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evaluated the maximal radiance into each biopsy. Again, 
the radical prostatectomy group had significantly higher 
maximal radiance than the radical cystoprostatectomy 
group (Figure 5C, Max radiance=1 790 058±610 571 vs 
539 638±568 550 p/s, p < 0.0001). As additional controls, 
we have infected separate biopsies from the same patients 
with an SV40 promoter driven fl adenovirus and did not 
observed statistical differences in the activities between 
the two groups (p = 0.27, data not shown). These results 
thus confirm that the PCA3-3STA system is indeed capable 
of specifically targeting primary PCa.
DIscUssION
In this study, we present a new transcriptional 
expression system, the PCA3-3STA, which specifically 
targets PCa cells in both primary PCa biopsies and 
PCa cell lines harvested from metastatic patients. By 
combining the promoter of a highly PCa-specific gene and 
a new transcriptional amplification system (3STA), we put 
forth that the PCA3-3STA system may be developed as 
a promising PCa-specific expression system not only for 
imaging but also for gene or immune therapy. 
To obtain imageable reporter activity from a weak 
Figure 4: PCA3-3STA detected primary prostate cancer cells from radical prostatectomy specimens ex vivo. A. 
Scheme of the technique developed. Prostate biopsy cores are harvested from radical prostatectomy (surgery performed to treat PCa) or 
cystoprostatectomy (surgery performed to treat bladder cancer in which the benign prostate is removed as well) specimens immediately 
after surgical removal. The biopsy cores are then co-cultured with PCA3-3STA adenovirus during 24 h after which they are cultured for 
48 h on a Gelfoam sponge. Three days after infection, the luciferase activity is measured using a CCD camera and is reported as p/s/
cm2 (Xenogen IVIS from Caliper Lifesciences). b. This procedure maintains PCa histological and specific biomarker expression such as 
prostate specific antigen (PSA), androgen receptor (AR), Ki67 or AMACR (positive in cancerous glands). c. Higher magnification of PCa 
histology and immunostainings as described in B). Note that the cytoplasmic AMACR staining is compatible with prostate cancer cells (e.g. 
see red arrows) while the nuclear stained cells correspond to p63 positive cells are found at biopsy periphery (see green arrow). Using this 
ex-vivo model, we show that PCA3-3STA-Luc adenovirus can detect primary PCa cells from radical prostatectomy specimens. Left panel: 
anti-firefly luciferase IHC, Middle panel: H&E staining; Right panel: anti-AMACR/p63 cocktail IHC. 
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promoter, such as the PCA3 promoter, we first had to 
construct and characterize the 3STA (Figure 1A), a 
derivative of the TSTA that harbours extra-Gal4 binding 
sites upstream of the PCA3 promoter. This enhanced 
system amplifies PCA3 promoter transcription by 95-fold 
(Figure 1B). Moreover, the PCA3-3STA is more specific 
for PCa cells than are the previously introduced MUC1, 
PSA, PEG-3 and hTERT promoter-based expression 
systems that can be active in many tissues or cancer 
subtypes [2, 22-24]. This is due in part to the observation 
that the 3STA not only amplified the PCA3 promoter 
activity, but also maintained its specificity for prostate 
cancer cells. In fact, none of the many non-PCa cell lines, 
nor primary benign epithelial cell lines or biopsies studied 
(Figures 2C, 2D, S1B, S2, 5) showed significant PCA3-
3STA activity when compared to PCa cells.
The data therefore suggest that once amplified by 
3STA, the PCA3 promoter activity displays specificity 
similar to that of PCA3 lncRNA for PCa, which is known 
to be overexpressed from localized PCa to CRPC [11, 25, 
26]. Its activity also matches that of PCA3 RNA that does 
not correlate with Gleason scores or pathological stage 
and is consistent with a high sensitivity for PCa detection 
using its promoter as a driver of 3STA. The underlying 
mechanisms of high PCA3 promoter specificity for 
cancerous prostate glands are as yet unknown. Verhaegh et 
al. clearly showed that the PCA3 (-152 to +62 bp) promoter 
displayed the strongest activity in LNCaP cells secondary 
Figure 5: PCA3-3STA activity can discriminate benign from primary cancerous prostate glands. Prostate biopsies were 
harvested from either radical prostatectomy specimens operated for prostate cancer or radical cystoprostatectomy specimens operated 
for bladder cancers. Each biopsy was then exposed to PCA3-3STA for 24 hours and then cultured for an additional 48 hours. PCA3-
3STA activity was then quantified after luciferin addition using a BLI apparatus. A. Representative biopsies of radical prostatectomy or 
cystoprostatectomy specimens after BLI. Four patients (3 biopsy per patient) in each group were imaged and the images shown represent 
the biopsy with the highest radiance for each patient. b. and c. Box plots were built from the photon emission quantification ((B) Average 
radiance (p/s/cm2), (C) Max radiance per biopsy (p/s)) obtained from 12 and 13 prostate biopsies from 4 and 5 consecutive patients in the 
PCa and benign groups, respectively. ****p < 0.0001.
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to an unidentified DNA-binding protein between the -29 
and -63 nucleotides [18]. However, while the proximal 
PCA3 promoter (-152 to +62 bp) did show some enhanced 
promoter activity in PCa cells, compared to that of benign 
or non-PCa cells, it was shown to be only 20 to 50% that 
of the weak SV40 promoter [17, 18]. Because PCA3 
lncRNA is overexpressed by 60-fold in PCa patients tissue 
samples when compared to benign patients tissue samples, 
other mechanisms than transcription seem to be involved 
in PCA3 RNA overexpression in PCa [11]. Furthermore, 
two groups have published on an alternative PCA3 gene 
transcript (PCA3TS4) using another transcription start site, 
136 bp upstream of the start site of the promoter which 
we have used (PCA3TS5 promoter) [12, 25]. Because the 
promoter of the PCA3TS4 transcript was not included in 
the constructs used, this alternative promoter does not 
contribute to the specificity observed with the 3STA. 
Moreover, Salagierski et al. showed that the PCA3TS4 
transcript expression levels accounted for only 1% of all 
PCA3 gene transcripts, suggesting a low activity of the 
promoter upstream of this transcript (so-called PCA3TS4) 
[25].
Of interest is that the PCA3 lncRNA (PCA3TS5) 
was androgen-induced [12, 25] whereas the PCA3-3STA 
was not (Figure 2E and 2F) which is in line with the 
absence of an androgen response element in the region of 
the PCA3 promoter used. This is a valuable characteristic 
of the system, as the ability to target both androgen-
sensitive and -insensitive PCa is of the utmost importance, 
what with the new challenges associated with CRPC 
metastasis detection by imaging, a prerequisite to systemic 
treatment. Recently, Salameh et al. have shown that the 
PCA3 lncRNA was an oncogene targeting the PRUNE2 
RNA, the later being a tumor suppressor gene in PCa 
[12]. Interestingly, PCA3 RNA was shown to hybridize 
to the RNA encoding PRUNE2 gene intron 6 to induce an 
adenosine deaminase acting on RNA (ADAR)-dependent 
degradation. This important study clearly shows that 
PCA3 is not only a biomarker but also a driver of PCa 
development and reinforce the importance to target PCA3 
overexpressing cells could definitely be exploited. 
Interestingly, the PCA3-3STA system shows 
reporter activity comparable to that of the PSEBC-TSTA 
both in vitro (Figures 2E, 2F and S2) and in vivo (Figure 
3). Given the extensive work performed using the PSEBC 
promoter in the TSTA system, it appears reasonable to 
assume that the gene therapy or imaging capabilities 
of the PCA3-3STA may be comparable to that of the 
PSEBC-TSTA, particularly for lymph node metastases 
or intraprostatic imaging by PET [5, 27]. The ability to 
discriminate benign from cancerous cells is particularly 
important in PCa, as the disease is usually low burden, 
multifocal, and well differentiated, all characteristics that 
limit accurate anatomical or metabolic imaging using 
classical metabolic PET tracers or magnetic resonance 
imaging (MRI). Moreover, as stated above, because the 
PCA3-3STA system is not designed solely for imaging, it 
could also be modified for gene or immunotherapy. With 
the recent clinical studies showing the effectiveness of the 
Sipuleucel-T and Prost-VAC immunotherapies in PCa, 
as well as the advent in clinics of checkpoint inhibitors 
[28], this system could be used to drive immunomodulator 
cytokines and/or cytotoxic genes to initiate a local or 
systemic immune response following intraprostatic 
injection. Indeed, the ability to combine transrectal 
intraprostatic delivery of the vector (avoiding adenoviral 
biodistribution problems), the PCa specificity of the PCA3 
promoter in primary PCa and the amplification provided 
by the 3STA make this system highly translational.
We acknowledge that our study did have its 
limitations. First, we did not directly demonstrate that 
the PCA3-3STA was capable of imaging PCA3 promoter 
activity using a clinical PET, as previously shown with 
the PSEBC promoter. We do believe, however, that 
because PCA3-3STA showed a higher specificity and 
sensitivity comparable to that of the PSEBC-TSTA, the 
potential of our system for immuno- and gene therapy 
or imaging certainly parallels and may even exceed that 
of previously reported vectors [5, 17]. Moreover, given 
that PCA3-3STA was PCa-specific, it was not possible to 
show its activity in large immunocompetent mammals, 
as it was performed for PSEBC-TSTA, which may image 
AR-dependent transcriptional activity in benign prostate 
epithelial cells [5]. Finally, the adenovirus as a delivery 
method may be subject to reluctance for security and 
biodistribution. However, we, as well as others, have 
shown that the prostate allows intratumoral transrectal 
adenovirus delivery and is therefore a unique cancer site 
easy to target [29]. Also, other delivery methods such as 
liposomes could be used to deliver the PCA3-3STA. 
cONcLUsIONs
This study presents a new PCa-specific expression 
system, the PCA3-3STA, based on the PCA3 oncogene 
promoter that matches the PCA3 lncRNA expression 
pattern. This system may indeed be used with significant 
accuracy to target PCa epithelial cells for imaging, 
vaccines, or gene therapy applications.
MAtErIALs AND MEtHODs
Plasmid construction and adenovirus production
The PCA3 promoter (-152 to +62 bp 
of Genbank accession number AF279290) 
was PCR-amplified from human genomic 
DNA with the following primers: PCA3-Fwd, 
CATGTAGCAAGCTTCCATGGCATATGTGTCAAC 
ATAGTGTGACGGGAAG and PCA3-Rev, 
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CATGTAGCAAGCTTCCACACAAATCTCCCCTCTGT 
[17, 18]. The PCA3 promoter was cloned upstream of 
the firefly luciferase (fl) gene in pENTR-L1L2 (Life 
Technologies, Burlington, ON, Canada) to obtain pENTR-
L1L2-PCA3-fl. Plasmid pENTR-L1L2-PCA3-fl was 
subcloned into pAd-pL-DEST by LR cloning (LR Clonase 
II Plus, Life Technologies) to obtain the adenovirus PCA3-
fl. For the construction of the PCA3-TSTA and PCA3-
3STA adenoviruses, we used the MultiSite Gateway® Pro 
2.0 kit (Life Technologies). First, the pDONR221-L1L2 
was used to obtain two different pENTR plasmids with 
multiple cloning sites, pENTR-L1R5-MCS and pENTR-
L5R2-MCS, containing attL1/attR5 and attL5/attR2 sites, 
respectively. GAL4RE (GAL4 response elements), first 
component of the TSTA along with the fl gene, was PCR-
amplified from pSh-TSTA-fl and cloned into pENTR-
L1R5 to obtain pENTR-L1R5-GAL4RE-fl. GAL4VP16, 
second component of the TSTA, was also amplified 
from pSh-TSTA-fl. The GAL4VP16 gene downstream 
of the PCA3 promoter was cloned into pENTR-L5R2 to 
obtain pENTR-L5L2-PCA3-GAL4VP16. The pENTR-
L1R5-GAL4RE-fl and pENTR-L5L2-PCA3-GAL4VP16 
plasmids were subcloned into pAd-pL-DEST by LR 
cloning to generate PCA3-TSTA adenoviral plasmid. The 
PCA3 promoter was replaced by the PSEBC promoter 
also amplified from pSh-TSTA-fl in the above-described 
plasmids to obtain the PSEBC-TSTA adenovirus. Another 
set of GAL4RE was cloned upstream of the PCA3 
promoter in the plasmid pENTR-L5L2-PCA3-GAL4VP16 
to obtain pENTR-L5L2-GAL4RE-PCA3-GAL4VP16 
which, along with pENTR-L1R5-GAL4RE-fl, was 
subcloned into pAd-pL-DEST by LR cloning to obtain the 
PCA3-3STA adenoviral plasmid. The adenoviral plasmids 
were then transfected into 293A cells for adenovirus 
production. Titers were determined using the Adeno-X™ 
Rapid Titer Kit (Clontech, Mountain View, CA, USA).
Cell cultures
22Rv1 (prostate cancer cell line), CAMA-1 (breast 
cancer cell line), and WPMY-1 (myofibroblast stromal 
cell line) were cultured in RPMI media containing 10% 
fetal bovine serum (FBS). LAPC4 (prostate cancer cell 
line) and HepG2 (liver cancer cell line) were cultured in 
DMEM media containing 10% FBS. PC-3 and DU145 
(prostate cancer cell lines), and MGHU3 and SW780 
(bladder cancer cell lines) were cultured in eMEM 
media containing 10% FBS. PZ-HPV-7 and benign 
primary cell cultures NPC1 and NPC2 (harvested from 
prostatic biopsies) were cultured in KSFM medium (Life 
Technologies), as previously described [30]. This study 
was approved by the Institutional Review Board of the 
CHU de Quebec Hospital, Quebec, QC, Canada. Each 
patient signed an informed consent form.
Adenoviral infection and androgen sensitivity
22Rv1 (1.6 x 105/well), LAPC4 (1.6 x 105 /well), 
PC-3 (6 x 104/well), DU145 (6 x 104/well), PZ-HPV-7 (8 
x 104/well), WPMY-1 (8 x 104/well), MGHU3 (8 x 104/
well), SW780 (8 x 104/well), and HepG2 (7 x 104/well) 
were seeded in 24-well plates. Twenty-four hours later, 
the PCA3-fl, PCA3-TSTA, PCA3-3STA, and SV40-fl 
adenovirus were added. Seventy-two hours after infection, 
cells were lysed and a luciferase assay was performed as 
described (Promega). For androgen sensitivity assessment, 
cells were treated with dihydrotestosterone (DHT) at 
10nM or bicalutamide at 10µM (Sigma-Aldrich, St.Louis, 
MO, USA) in 10% charcoal-stripped FBS, 24h post-
infection. Luciferase assays were performed after 48 h of 
treatment.
Time course experiments and western blot 
analysis
22Rv1 cells (1.6 x 105/well) were seeded 24h 
prior to infection with PCA3-fl, PCA3-TSTA and PCA3-
3STA. Relative luciferase unit (RLU) was assayed at the 
indicated time points for each virus. Western blot analysis 
was performed on the collected lysates with 4µg of protein 
and the membranes were incubated with antibodies against 
β-actin (1:5000, Sc47778, Santa Cruz, CA, USA) or vp16 
(1:5000, ab4809, Abcam, Toronto, ON, Canada). The 
secondary antibodies (1:5000) were conjugated with 
IRDye™ 680-anti-mouse and IRDye™ 800-anti-rabbit 
antibodies (LI-COR, Lincoln, NE, USA). Proteins were 
detected and the signal was quantified by means of the 
Odyssey Scanning System (LI-COR, Lincoln, NE, USA).
In vivo experiments
Two million 22Rv1 and LAPC4 cells mixed in 
Matrigel (354262, Fisher Scientific, Ottawa, ON, Canada) 
were injected subcutaneously into the flanks of Fox Chase 
SCID beige mice (code 250, Charles River Canada, St-
Constant, QC, Canada). Tumors were grown for 32 
days. The adenoviruses (108 infectious viral particles 
(ivp)) in phosphate buffered saline (PBS) were injected 
intratumorally. Ninety-six hours later, bioluminescence 
was quantified using a CCD camera and is reported as p/s/
cm2 (Xenogen IVIS, Caliper Lifesciences, Woodbridge, 
ON, Canada). All of the animal experiments were 
approved by the Laval University animal care committee.
Ex vivo primary PCa detection
Biopsy cores (18G, 17mm) were taken from the 
prostate peripheral zone following removal by robotic 
radical prostatectomy or radical cystoprostatectomy 
Oncotarget1309www.impactjournals.com/oncotarget
performed to treat PCa or bladder cancer, respectively 
(see Supplemental Table S1). Sextants harboring PCa at 
the transrectal biopsy and a nodule were targeted. The 
biopsies were washed with PBS and cultured for 24 hours 
in eMEM-10%FBS supplemented with 10nM DHT and 
antibiotics and the PCA3-3STA (107 ivp) adenovirus under 
gentle shaking. The biopsies were then transferred on a 
Gelfoam soaked into fresh media for another 48h, after 
which time luciferin was added and the luminescence 
activity was imaged by means of Xenogen IVIS [31]. The 
biopsies were then fixed in 10% formalin and embedded 
in paraffin. Five-μm sections were analyzed with either 
H&E staining or immuno-histochemical staining (IHC). 
The luciferase IHC was performed with the IDetect Super 
Stain System HRP (IDST1007, ID Laboratories, London, 
ON, Canada) with anti-luciferase (1:7000, 70R12141, 
Fitzgerald, Acton, MA, USA) as the primary antibody 
and Donkey anti-Goat antibody (1:500, Ab6884, Abcam, 
Toronto, ON, Canada) as the secondary antibody. The IHC 
with the PSA, androgen receptor (AR), Ki67 or cocktail of 
AMACR/p63 antibodies were performed by the clinical 
pathology facility at the CHU de Quebec Hospital using a 
standard clinical protocol.
Statistical analysis 
All of the statistical analyses were conducted using 
the T-test with Welch’s correction, with (****) indicating 
p = < 0.0001, (**) indicating p = < 0.01 and (*) indicating 
p = < 0.05.
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